JOURNAL OF BUON, vol.24, no.6, pp.2327-2332, 2019 (Journal Indexed in SCI)
Article / Article
Title of Journal :
JOURNAL OF BUON
pazopanib, sarcoma, uterus, uterine sarcoma, SOFT-TISSUE SARCOMA, PHASE-II TRIAL, EUROPEAN ORGANIZATION, LEIOMYOSARCOMA, GEMCITABINE, DOXORUBICIN, UTERUS, DOCETAXEL, BONE, CHEMOTHERAPY
Purpose: Uterine sarcoma accounts for 3-9% of uterine malignant tumors and has poor prognosis. Pazopanib is an oral multi-kinase inhibitor and the only tyrosine kinase inhibitor which has been approved for metastatic soft tissue sarcoma. In the present study we aimed to evaluate the efficacy of pazopanib in metastatic uterine sarcoma.